BJMO - 2022, issue Special, may 2022
A. Enguita PhD, T. Feys MBA, MSc
In recent years, researchers have evaluated the integration of immunotherapy in the perioperative management of patients with muscle invasive bladder cancer (MIBC), with mixed results. During BMUC 2022, Professor Richard Cathomas (Division of Oncolgy, Cantonal Hospital Graubünden, Switzerland, and University of Zurich, Switzerland) provided an overview of these advances.
Read moreBJMO - 2022, issue Special, may 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
Over the past years, next-generation imaging such as multiparametric whole body MRI and PSMA-PET/CT scans have been gaining momentum. Nonetheless, Prof. Padhani argues not to throw bone scintigraphy and CT scans (BS/ CT scans) out just yet. On the contrary, he puts BS/CT scans at the centre of patient care in men with locally advanced prostate cancer (LAPC). However, BS/ CT also comes with important limitations for which next-generation imaging (NGI) can serve as a problem solver after BS/CT scan assessments. During his talk at the BMUC 2022 meeting, Prof. Padhani emphasized the proven prognostic role of BS/CT scans, their predictive role in directing pelvic radiotherapy and for oncologic drug development. Finally, he argued that higher-quality evidence on the management and/or outcomes is needed before BS/CT scans can be substituted by NGI.1
Read moreBJMO - 2022, issue Special, may 2022
A. Dekker MD, T. Feys MBA, MSc
About 15% of patients with localised prostate cancer (PCa) are identified as having a high risk for disease recurrence and these patients account for the vast majority of PCa deaths. To date, however, the optimal treatment for patients with high-risk, localized PCa remains controversial. While it is important to offer these patients an effective treatment, this treatment should not come with excessive side effects or impact the patient’s quality of life (QoL).1 During a session at the 2022 BMUC meeting, the different treatment options for these patients were discussed from the perspective of the surgeon, the medical oncologist and the radiation oncologist.
Read moreBJMO - 2022, issue Special, may 2022
A. Dekker MD, T. Feys MBA, MSc
What is the role of the patient in the management of prostate cancer? During BMUC 2022, André Deschamps, prostate cancer (PCa) patient and Chairman of Europa UOMO aimed to answer this question. In his lecture, he discussed the effect of PCa and its treatment on the daily life of patients and addressed some of the barriers and gaps that hamper a closer involvement of patients in the treatment decision process. 1
Read moreBJMO - 2022, issue Special, may 2022
T. Feys MBA, MSc
The second day of the 2022 annual BMUC meeting kicked off with a session addressing three hot topics in the field of kidney cancer. In a first lecture, Prof. Dr. Toni Choueiri (Dana Farber Cancer Institute, Boston, MA, USA) discussed the management of patients with non-clear cell renal cell carcinoma (RCC). Subsequently, Dr. Marco Gizzi (GHdC, Charleroi) turned the attention to the adjuvant treatment of patients with RCC after which he gave an overview of new molecules for patients with metastatic RCC. Dr. Stephanie Kroeze (Universitätsspital Zürich, Zürich, Switzerland) closed the RCC session with a presentation on how to combine radiotherapy with systemic therapy in this setting.
Read moreBJMO - 2022, issue Special, may 2022
A. Enguita PhD, T. Feys MBA, MSc
In line with the tradition, the BMUC scientific committee asked a urologist, a radiation oncologist, and a medical oncologist to summarise the top stories presented during the large urology and oncology meetings of the past year.
Read moreBJMO - 2022, issue SPECIAL, february 2022
J. Blokken PhD, PharmD, T. Feys MBA, MSc
The breast cancer task force session of the Belgian Society of Medical Oncology (BSMO) annual meeting reviewed the most important recent data on advanced HER2-positive breast cancer and triple negative breast cancer (TNBC). First, Dr. Eline Naert (University Hospital Ghent) discussed the treatment algorithm for advanced HER2-positive breast cancer anno 2022. Prof. Francois Duhoux (UCLouvain) subsequently addressed the current and emergent treatment options for patients with early or locoregional advanced triple-negative breast cancer. Finally, Prof. Christos Sotiriou (Institut Jules Bordet) closed the session by further dissecting the TNBC heterogeneity through molecular profiling and special transcriptomics.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
